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Abstract
Background: Pragmatic trials have been suggested as a way to improve the relevance of clinical trial results to
practice. PRECIS-2 (Pragmatic Explanatory Continuum Indicator Summary-2) is a trial design tool which considers
how pragmatic a trial is across a number of domains. It is not known whether a pragmatic approach to all PRECIS-2
domains leads to results being more relevant to primary care. The aim of this study was to investigate the views of
people with influence on primary care practice towards the design of randomised trials, pragmatic approaches to
trial design, and the PRECIS-2 domains.
Methods: We carried out semi-structured interviews with people who influence practice in primary care in the UK.
A thematic analysis was undertaken using the framework approach.
Results: We conducted individual or small group interviews involving an elite sample of 17 individuals. We found
that an exclusively pragmatic approach to randomised trials may not always make the results of trials more
applicable to primary care. For example, it may be better to have less flexibility in the way interventions are
delivered in randomised trials than in practice. In addition, an appropriate balance needs to be struck when
thinking about levels of resourcing and the intensity of steps needed to improve adherence in a trial. Across other
aspects of a trial’s design, for example the population and trial setting, a pragmatic approach was viewed as more
appropriate.
Conclusions: To maximize the relevance of research directed at primary care, trials should be conducted with the
same populations and settings that are found in primary care. Across other aspects of trials it is not always
necessary to match the conditions found in practice.
Keywords: Pragmatic clinical trial, Primary health care, Randomised controlled trial, PRECIS-2
Background
Randomised trials are seen by many as being the best
design for providing evidence about the effectiveness of
different interventions. However, they do not always
produce evidence that is relevant to primary care
because they are frequently conducted under conditions
that are different from those found in primary care
[1, 2]. In addition, primary care faces restrictions on
resourcing [3] and a need for complex interventions,
involving multiple interacting elements [4]; two factors
that can further complicate the adoption of new
interventions.
Pragmatic trials have been suggested as a solution to
the problem of evidence not being relevant to clinicians,
policymakers and patients. Pragmatic trials are often
thought of as randomised trials that test interventions
under the conditions found in routine care: aside from
aspects of routine care modified by the intervention
itself, other aspects of care should be as they usually
would be [5–10]. Research funders including the
National Institute of Health Research (NIHR) in the UK
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[11], the National Institute of Health (NIH) [12] and Pa-
tient Centred Outcome Research Institute (PCORI) [13]
in the USA aim to fund pragmatic trials. There is growing
interest in pragmatic trials from the pharmaceutical indus-
try with the GetReal collaboration aiming to show how
real world evidence, including pragmatic trials, could be
used in pharmaceutical research and development [14].
When designing pragmatic trials, compromises often
need to be made as routine care conditions cannot always
be replicated within the trial. PRECIS-2 [15] (Fig. 1) is a
trial design tool which has been developed to help make de-
cisions about a trial’s design, by highlighting how pragmatic
a trial is across nine different domains: eligibility, recruit-
ment, setting, organisation, flexibility of delivery, flexibility
of adherence, follow up, primary outcome, and primary
analysis. The tool can be used to help investigators reflect
on the design of their trial and ensure choices they have
made allow the trial to achieve its goals. PRECIS-2 can be
applied to individually randomised trials, cluster rando-
mised trials [17] and also to systematic reviews [18].
To date, little research specific to primary care has
been conducted to help those designing pragmatic trials
make decisions to maximise the relevance of their results
to practice. In particular we are aware of no research
that considers the views of those implementing new re-
search in this setting towards the compromises those
designing trials may have to make. Previous research
highlights challenges in defining complex interventions
in pragmatic trials, deciding what steps should be taken
to ensure compliance, and deciding the level of flexibility
given to those delivering the intervention [1, 19, 20].
The aim of this study is to explore the views of stake-
holders involved in influencing clinical practice in primary
care towards the design of randomised trials. We investi-
gate how evidence from trials is used and which aspects of
a trial’s design influence how the results are interpreted.
General views about pragmatic trials are explored and the
PRECIS-2 tool is used to facilitate a discussion about spe-
cific decisions researchers can take to maximise the rele-
vance of their trials to primary care.
Fig. 1 PRECIS-2 wheel for the COPERS [16], a largely pragmatic trial. For each domain higher scores indicate a more pragmatic approach and
lower scores a more explanatory approach
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Methods
We conducted individual and small group interviews to in-
vestigate the views of people involved in influencing pri-
mary care practice on how best to design trials and on
views towards areas of design covered by the PRECIS-2 do-
mains. We sampled from groups who had a professional
interest in the wider dissemination of research findings into
primary care practice.
Through research team discussion and consultation with
academics in primary care, we identified seven categories of
people who used the results of primary care trials to influ-
ence practice, and aimed to include people from each cat-
egory in our sample. The different categories were journal
editors, primary care educators, guideline developers, re-
search charities, research funders, clinical commissioning
group leads and quality improvement organisations. Re-
search funders were included as their role in deciding what
research gets carried out has considerable implications for
how clinical practice evolves. Research charities were in-
cluded as a category due to their work in funding research
and because of the work they do advocating for changes in
health policy and clinical practice.
We identified individuals from each category either from
appropriate websites or through personal networks of the
research team and approached via email. The invitation
email described the work as a “study investigating how best
to design and conduct clinical trials in primary care so that
they deliver results that are relevant to practice” and in-
formed potential participants that we would be using
PRECIS-2 and provided a brief description of the tool. We
invited participants until we had at least one person from
each category. We invited more than one person in each
category at a time to maximise recruitment; if more than
one person from a category responded to our invitation we
interviewed all of them. The sample size was limited as the
study targeted an elite group of stakeholders tasked with
the job of synthesising and rolling out research evidence.
The interviews were carried out by GF (Gordon Forbes),
either face to face or via video link (Skype). Face to face in-
terviews were carried out at the participants place of work
or in another location of their choosing. The interviews
were scheduled to last 1 h and lasted between 45min and
1 h 15min. At the time of the interviews GF was a male, re-
search methods fellow who had received training in qualita-
tive research methods. For two interviews GF was joined by
a male academic GP who co-led the interview. The aca-
demic GP had received training in qualitative research and
had experience conducting qualitative research. All partici-
pants were unknown to the interviewers prior to the inter-
views taking place.
GF (Gordon Forbes) developed the topic guide for the
interviews through discussions with the research team.
This guide was refined throughout the research process,
for example some vignettes of trials used in early
interviews were dropped from later interviews because
discussion of these vignettes left little time for discussion
of other important topics. The final topic guide is re-
ported in Table 1.
Prior to the interviews participants provided consent to
participate in the study. Interviews were recorded and tran-
scribed by an independent transcription service. One inter-
view was transcribed by GF. Transcripts and findings of the
study were not returned to participants for comment.
A thematic analysis was carried out following the Frame-
work method [21]. Familiarisation was carried out by four of
the study authors (GF, SE (Sandra Eldridge), KL (Kirsty Lou-
don) and MC (Megan Clinch)): GF read all of the interview
transcripts and notes. SE, KL and MC each read a different
subset so that all the interview transcripts were reviewed by
two different people. Analysis was conducted using NVivo
version 10. A thematic framework was developed by GF and
reviewed with SE, KL and MC. Coding was conducted by
GF and codes were reviewed and discussed with SE, KL and
MC. Indexing and Charting were carried out by GF and
reviewed by SE, KL and MC. Interpretation of the results
was carried out by all authors of the study.
Results
We sent 24 invitations to groups or individuals to par-
ticipate in the study; we conducted 12 interviews and 12
invitations were declined. Seventeen individuals took
part in total, nine via individual interviews and eight via
group interviews (Table 2). Interviews were conducted
between October 2014 and February 2015. Three of the
individual interviewees did not give permission for their
interviews to be recorded. For two interviews the record-
ing equipment failed so in total seven interviews (two
group and five individual) were recorded and
Table 1 Topic guide
• Interviewer introduction—GF introduced himself and the study. He
introduced himself as a researcher interested in pragmatic trials,
describing the research as a study into how best to design primary care
trials so that they are relevant to practice. PRECIS-2 is mentioned in passing
but not the details of how the tool works. Where the academic GP was
present they were introduced as a GP with research interests similar to GF
• Participant(s) introduction
• How participants use evidence from randomised trials
• What aspects of trials do participants think are important when
deciding whether research is relevant to practice
• PRECIS-2 is introduced by the interviewer with the participant shown
an example PRECIS-2 wheel. The concepts of pragmatic and explanatory
trials are also explained
• How important is it that research is similar to routine practice for
each of the PRECIS domains for the results of the trial to be relevant to
practice?
• Closing. Interviewee(s) is asked if there is anything else they would
like to say or comment on and given the opportunity to ask any
questions they have about the study
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transcribed. We used contemporaneous field notes from
the remaining five interviews.
Four main themes emerged from our interviews: how
evidence is used; aspects of trials considered when asses-
sing evidence; views on PRECIS-2 domains; and percep-
tions of pragmatic and explanatory trials.
How evidence is used
Interviewees who applied evidence from randomised trials
in a clinical setting reported using evidence differently from
those who produced evidence synthesis or guidelines. The
latter followed a formal process starting with a systematic
way of identifying evidence, critical appraisal and then pro-
duction of a summary of the evidence as a review or guide-
line. Challenges in applying evidence came from combining
the results of heterogeneous evidence and deciding whether
evidence is applicable to the question of interest. In over-
coming these challenges judgement has to be incorporated
into the formal processes. The greatest area of judgement
was around whether evidence is applicable to the question
of interest.
“[the guideline development group members] make,
what we call, a considered judgement on evidence
from the trials, taking into account other aspects,
whether it’s generalizable, whether it’s applicable.”
(Interview C, Guideline developer)
For those applying evidence in a clinical setting, sources
of evidence included guidelines or evidence summaries as
well as less formal sources such colleagues or experts in a
particular field. Due to time pressure and a need for ac-
countability regarding decisions about patient care, the
results from single studies were not commonly used to in-
fluence practice. We found a mistrust of early evidence
due to the potential of trials to show greater benefit of
new interventions than would be found in practice. To
overcome this challenge some individuals employed a de-
liberate strategy of waiting before implementing new evi-
dence. A further challenge in applying evidence was the
limited resources to implement novel interventions.
“So most of the time, what you’ll find is on my
computer screen [is], NICE [The National Institute for
Health and Care Excellence] or CKS [Clinical
knowledge summaries] open up in a separate window,
that I’ll just refer to if I need to with every patient.”
(Interview E, Primary care educator)
“…let’s just take the new oral anticoagulant agents …
There’s been some early meta-analyses, but everybody
feels the early trials were always more optimistic…
(Interview D, Primary care support and quality
improvement)
“…the question is, do you wish to be an early adopter,
are the advantages so great that you want to take a
risk or would you like to do it later.”
(Interview D, Primary care support and quality
improvement)
Interviewees from the research charity were involved
in advocating for change based on the results of new re-
search and facilitating discussions amongst clinicians of
Table 2 Summary of interviews
Interview Number of Interviewee(s) Role Primary Care Clinician
Interview A* 3 Guideline developer No
Interview B 1 Guideline developer No
Interview C* 1 Guideline developer No
Interview D 2 Primary care support and quality improvement Yes
Interview E 1 Primary care educator Yes
Interview F 1 Primary care commissioner Yes
Interview G 3 Research charity (two members of research funding team,
one member of research policy team)
No
Interview H† 1 Chair of public funding panel Yes
Interview I† 1 Chair of public funding panel No
Interview J† 1 Health technology assessment No
Interview K† 1 Editor of journal publishing systematic reviews No
Interview L† 1 Clinical director of journal publishing systematic reviews No
*Academic GP co-lead interview
†Only field notes available for interview
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issues arising in new evidence. They focused on trials
funded by their charity. Rather than applying a formal
process of critical appraisal they appeared to try to
ensure quality by funding research meeting certain
standards.
“And we also use [examples of clinical trials funded by
the charity] quite heavily in case studies when we’re
talking to government, just as examples of how
charities operate in the UK and demonstrations of
exciting new things that are happening.”
(Interview D, Primary care support and quality
improvement)
The funders interviewed provided perspectives on the use
of evidence but from their roles as clinicians and as re-
search funders. From the perspective of funders they advo-
cated that research be disseminated via systematic reviews
and guidelines. As clinicians their views towards evidence
use were consistent with those already presented.
“Systematic reviews of all relevant research should be
carried out and these should be disseminated and
used to change practice. This is where organisations
such as NICE can play an important role in producing
guidelines based on the best evidence.”
(Interview I, Research funder)
Perceptions of pragmatic trials
Interviewees perceptions of pragmatic trials included
enthusiasm, mistrust alongside limited knowledge of the
term and misconceptions about its meaning. Interviewees
from public research funders and journals were most en-
thusiastic about pragmatic trials, showing existing familiar-
ity with the concept and positively expressing that those are
the sort of trials they would be most interested in.
“We are more interested in funding pragmatic trials
than explanatory and would like to see trials which
were as pragmatic as possible...”
(Interview H, Research funder)
Interviewees from the research charity, involved in pri-
mary care education or from CCGs, and some inter-
viewees involved in guideline development had little pre-
existing knowledge of the term “pragmatic trials”, ex-
pressing misconceptions as to what the concept meant
or it being a term they were not familiar with prior to
the interview. Misconceptions about pragmatic trials in-
cluded conflating the design with trials of complex
interventions and with particular design features such as
cluster randomisation or open label studies. It was also
suggested that pragmatic trials would only be relevant to
in particular clinical areas. Some interviewees also drew
a distinction between pragmatic trials and randomised
controlled trials.
“...to include [pragmatic trials] the guideline
developers would have to be really careful to explain
the difference between this and RCT [randomised
controlled trial].”
(Interview C, Guideline developer)
Amongst those who used evidence from guidelines or
evidence synthesis, pragmatic trials were welcomed as
they simplified the judgement around whether evidence
is applicable to clinical settings. There was concern,
however, that they could be significantly different from
trials in the existing evidence base leading to heterogen-
eity which could make meta-analysis more difficult.
“Pragmatic trials may have to be considered
separately in meta-analysis due to heterogeneity with
other trials”
(Interview J, Health technology assessor)
“I can just imagine that people would be really thrilled
to see a pragmatic trial, of diabetes or something, [set
here] and that people could then use it... It would be
so much better for recommendations.”
(Interview C, Guideline developer)
Pragmatic trials also carried negative connotations,
sometimes being viewed as inferior to more traditional
approaches to randomised trials due to perceived
weaknesses.
“Pragmatic can be a dirty word when describing trials,
people like to shoot at them…”
(Interview K, Editor of Journal publishing systematic
reviews).
There was also concern that the degree of pragmatism
of trials could be used to manipulate the systematic re-
view process.
“During discussions of evidence it can be difficult to
consider the relative pragmatism of
evidence—sometimes it is used by people to try and
exclude evidence that doesn’t agree with their point.”
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(Interview I, Research funder)
Views on the PRECIS-2 domains
The population in the trials was by far the most dis-
cussed aspect of a trial’s design, with interviewees prefer-
ring trial populations to have few exclusions, including
patients with comorbidities and older patients. Popula-
tion is handled by PRECIS-2 over three domains: eligi-
bility, recruitment and setting (Fig. 1).
“So again, if you do it in your tertiary centres, then it
becomes almost inapplicable in primary care, because
I don’t have those resources. I don’t see all of those
patients at that stage in that illness. I see them either
way before or way after they’ve seen the tertiary care
people. So yes I think setting is very important.”
(Interview E, Primary care educator)
Aside from its part in determining the population in
trials, recruitment was an aspect of trial design not expli-
citly considered by most interviewees when assessing
evidence. Amongst those who did consider the impact of
recruitment on the relevance of trial results, there was
concern that very intensive recruitment could lead to
people being included in trials who would not usually
present for treatment in routine practice.
“…we wouldn’t assess recruitment routinely, but it’s
about whether recruitment is applicable to the
question that we‘re trying to address.”
(Interview D, Guideline developer)
“Sometimes recruitment can be too intensive and bring
people into the trial who would not usually present for
a condition”
(Interview I, Chair of funding panel)
The organisation domain focuses on the level of
expertise and resources made available to deliver an
intervention compared with what would be available
in practice. Here, we identified a tension between a
pragmatic and an explanatory approach. Those apply-
ing research in practice were more concerned about
resourcing issues and preferred trials to test interven-
tions that could be implemented with the limited re-
sources available in primary care. Those from the
research charity or guideline developers believed there
was also a place for evidence from trials of interven-
tions requiring resources over and above those cur-
rently available. They felt that sometimes research
showing that a resource-intensive intervention was ef-
fective could lead to those resources becoming avail-
able in routine care.
“The only thing in primary care that would be a
limiting factor is the resources aren’t this sort of
overflowing bucket”
(Interview E, Primary care educator)
“And sometimes groups will make the gold standard
recommendation and that will push forward what
resources are brought in”
(Interview C, Guideline developer)
For flexibility of delivery interviewees producing evi-
dence synthesis or guidelines favoured reduced flexibility
as this allows more understanding to be gained as to
what is causing any effect, makes it easier to include a
trial in a meta analysis and also reduces bias from other
treatments being initiated. Reduced flexibility was also
preferred as it allowed greater understanding of what the
intervention being delivered in the trial actually is. For
the clinicians interviewed there was an appreciation and
expectation that trials would have less flexibility in the
way interventions were delivered.
“ After ten years of doing this I would prefer to see
strict control [in how interventions are delivered] but if
there are variation they need to be described properly
so in attempting to make sense of this you can see
what has happened.”
(Interview B, Guideline developer)
“We appreciate that you’ve got to stick to strict
guidelines when you’re doing the research, otherwise it
doesn’t become very accurate at the end of it. So as
long as it’s not hugely different, we appreciate there is
a little bit of leeway in real life, but we wouldn’t
expect that in a clinical trial.”
(Interview E, Primary care educator)
Poor adherence to interventions in trials was a con-
cern as this can reduce the potential effect of a success-
ful intervention. For some, best practice with regard to
flexibility of adherence was for adherence issues to be
identified prior to the trial and in the trial itself no extra
steps to be taken to improve adherence. Others, notably
the interviewees from the research charity, suggested
knowing an intervention can be effective can lead to
measures to help adherence being developed.
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“Researchers shouldn’t include intense follow-up to en-
sure adherence. Steps should be taken to collect as
much primary end point data as possible but this is
separate to ensuring that people adhere to the
intervention.”
(Interview I, Chair of funding panel)
“The more flexibility there, the more you’re going to
actually mask any real effect because of the amount of
variation... ...find out why people aren’t adhering and
what can we do to try and help people adhere to that
particular exercise programme, for example. So, you
know, I feel that the flexibility [of adherence] should be
pushed tighter.”
(Interview G, Research funding and policy, Research
charity)
For follow-up we identified a balance to be struck be-
tween collecting data that are useful for research and
follow-up influencing participant behaviour or increasing
the burden on those taking part. There was also concern
raised by some interviewees that in some settings inten-
sive follow-up could act as an additional intervention.
“ ...in terms of having quite a lot follow up, you can get
some really useful answers and actually you probably
want to do that. But it’s thinking about the way in
which you follow-up and so that you’re not actually
influencing their behaviour and their clinical outcome
through taking those measurements.”
(Interview G, Research funding and policy, Research
charity )
Where primary outcome and primary analysis were
discussed all interviewees favoured a more pragmatic
approach with patient-centred primary outcomes and
intention to treat analysis. There was concern expressed
about primary outcomes being measured at too early a
time point.
Comments on applying PRECIS-2
The guideline developers, research charity and research
funders considered PRECIS-2 a useful tool, with the
guideline developers saying that it covered many of the
areas of judgement they were required to make and
those involved in research funding commenting that be-
ing able to justify design decisions across the PRECIS-2
domains would strengthen funding applications.
“we never used this instrument, it looks very helpful,
we were often left to make the judgement... to what
degree was it moving towards the pragmatic, and to
what degree was it explanatory.
(Interview B, Guideline Developer)
“if they thought about all of them in advance and
they’ve got a good reason why it’s explanatory on this
and it’s pragmatic on this one, then I think that’s, that
would make a strong application coming through.”
(Interview G, Research funding and policy, Research
charity)
Alternative uses for PRECIS-2 were also suggested, in-
cluding use as a teaching aid, trial reporting, and aiding
judgements around applicability. It was noted that
PRECIS-2 is subjective so care would have to be taken
for reported PRECIS-2 scores to be justified.
“…actually in the paper they should put [PRECIS-2
wheels] in… you just want a quick summary. That
might be helpful”
(Interview F, Primary care commissioner)
Issues raised by participants but not covered by PRECIS-2
domains
Outside of PRECIS-2 domains, interviewees raised issues
around internal validity, in particular blinding where
possible, and size of the trial, with larger trials preferred.
Internal validity, sometimes referred to by interviewees
as “quality”, was typically assessed before generalisability
when developing guidelines or assessing research for
funding, typically using risk of bias tools. Issues around
internal validity were raised both by those involved in
evidence synthesis and by those applying evidence to
practice.
“So if the quality is poor, that will get marked before
people even think whether it’s generalisable or not.”
(Interview C, Guideline developer)
Of the factors unrelated to the design of trials, report-
ing of the trial was the most important issue outside
PRECIS-2 domains to be raised. Poor reporting was seen
as an obstacle to using evidence in practice whereas
good reporting was seen as something which could en-
hance the generalisability of evidence. Areas of reporting
that were most important included details of what the
intervention was, how the intervention was implemented
in the trial and discussion of the generalisability of re-
sults. If usual care is used as a comparator, it was seen
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as important to report in detail what usual care con-
sisted of.
“I think we’ve found that people have not been able to
use evidence before because they haven’t been clear on
what the usual care has been.”
(Interview C, Guideline developer)
Other issues that were raised included patient accept-
ability of the intervention, whether research was carried
out in collaboration with practice and whether the inter-
vention addressed an important clinical problem either
effecting a large number of people or a particular prob-
lem for a minority that has been hard to reach.
Discussion
Summary
Whilst broadly supporting the principle of pragmatic tri-
als, this study identifies a number of issues that those
conducting and funding trials of interventions to be
delivered in primary care should take into account to
improve the relevance of the research to primary care.
The term “pragmatic trial” is not universally recognised
and sometimes misunderstood. Whilst pragmatic trials
were welcomed by some of our interviewees, others
showed less familiarity with the concept or expressed
suspicion towards trials labelled as pragmatic due to a
perceived lack of rigour.
Across the PRECIS-2 domains eligibility, setting, pri-
mary outcome and primary analysis the universal re-
sponse from our interviewees was that more pragmatic
trial designs would make results most useful. In particu-
lar including the same population as would present in
practice, having patient centred outcomes and conduct-
ing intention to treat analysis.
For the domains recruitment, flexibility of adherence,
organisation, follow-up, a balance needs to be struck be-
tween testing the intervention under more restricted
conditions and a more pragmatic approach. For recruit-
ment and follow up, it was acknowledged by some inter-
viewees that for trials to be successful they cannot
mirror routine care, and a slightly less pragmatic ap-
proach could be necessary. However, extreme departures
from routine care for follow-up or recruitment were dis-
couraged, in particular for follow-up where interviewees
were concerned about intensive follow-up influencing
behaviour.
For organisation and flexibility of adherence there was
a tension between recognising the limitations that an
intervention will encounter in everyday practice and pro-
viding results that can lead to change. Showing an inter-
vention is effective when delivered with greater
resources or expertise than can be found in practice
could lead to better resourcing being made available.
Similarly, showing that high adherence to an interven-
tion leads to better outcomes could motivate efforts to
improve adherence to treatments. There was a contrast
in responses between the clinicians interviewed and
some of our other interviewees, most notably those from
the research charity. The clinicians generally favoured a
more pragmatic approach, taking into account the con-
straints of the system in which they worked. Inter-
viewees from the research charity and involved in
guideline development saw a place for designs that are
less pragmatic in terms of organisation or flexibility of ad-
herence as these trials may provide evidence that leads to
system level. It is worth noting that delivering interven-
tions with greater levels of resources than can be found in
practice may be challenging with some public funders as
research funding does not necessarily cover excess treat-
ment costs [22].
For flexibility of delivery a less pragmatic approach
was favoured. Being able to clearly identify the interven-
tion delivered in a trial was more important to our par-
ticipants than trying to reproduce in the trial the
amount of flexibility that would exist in practice when
delivering interventions.
Our findings relating to how evidence is used by clini-
cians are not new and have been explored in more detail
by others [23]. It is worth noting, however, that clini-
cians routinely accessed evidence from clinical trials via
guidelines, highlighting the importance of trials being
conducted in a way that is amenable to the guideline de-
velopment process. One of the key challenges identified
for those developing guidelines is assessing whether evi-
dence is applicable. In addition, good reporting, particu-
larly details of the intervention, can enhance the
applicability of a trials results. Steps taken to maximise
internal validity are also important, for example blinding,
as this is often assessed before the applicability of trials
is considered.
Strengths and limitations
This study sought the views of people from a variety of
backgrounds involved in applying evidence from rando-
mised trials towards the design of pragmatic trials,
obtaining a wide range of views highlighting aspects of
design where there is consensus and areas where deci-
sions are more contentious. The study included a limited
elite sample and was not designed to achieve saturation.
There was evidence of saturation across the themes of
“How evidence is used”, “aspects of trials considered
when assessing evidence” and “views on the PRECIS-2
domains”, with our later interviews bringing limited new
views. For our fourth theme, “perceptions of pragmatic
and explanatory trials”, we found a wide range of views
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and whilst there was repetition of some of the key ideas
we cannot be certain saturation was reached.
The researchers conducting the study presented them-
selves as researchers involved in carrying out pragmatic
trials, so more critical views of pragmatic trials may not
have been encountered. Whilst the sample did not in-
clude primary care clinicians as a separate category a
number of clinicians were included, ensuring that their
contributions are well represented. All stages of data
analysis involved at least four different researchers, help-
ing to avoid the interpretation of the results being
dependent on the interpretation of a single person.
Discussing PRECIS-2 in interviews presented chal-
lenges as it was only possible to convey a relatively
superficial level of understanding of the tool. On the
other hand the use of PRECIS-2 enabled a detailed dis-
cussion of the specifics of pragmatic trial design, without
relying on the interviewees’ understanding of what it
means for a trial to be pragmatic.
Comparison with existing literature
This study is the first to examine pragmatic trials from
the point of view of those funding and disseminating evi-
dence for primary health care. Too much flexibility in
the way interventions are delivered has been identified
as posing problems in pragmatic trials in three previous
studies [24–26]. These studies raise concerns about the
challenges too much flexibility may present to those de-
livering the intervention [25] and identify safety con-
cerns when implementing a new intervention without
strict guidelines [26]. The tension between fidelity to the
intervention and its delivery and flexibility so that the
intervention can be implemented widely is also de-
scribed in implementation research [27]. The trade-off
between testing interventions within the resource con-
straints found in practice, and conducting trials that can
lead to better resources in practice, has not received
much attention previously in the pragmatic trial litera-
ture. The need for enhanced descriptions of interven-
tions has been identified for complex interventions [28]
and is highlighted in the consort extension for pragmatic
trials [8], and the TIDiER checklist for reporting inter-
ventions [29].
Future research
Further work in this area could explore whether the find-
ings of this study are generalisable to other clinical set-
tings. Work to improve adherence to existing reporting
guidelines [8, 29] could also improve the generalisability
of trial results in primary care. Closer collaboration be-
tween trialists conducting pragmatic trials and people in-
volved in evidence synthesis and guideline development
could help ensure new trials fit smoothly into the guide-
line development process.
Conclusions
Funders and trialists investigating interventions that will
be applied in primary care should fund and conduct ran-
domised trials that are pragmatic in terms of the popula-
tion included in the trial, the setting and trial outcomes.
Particular care should be taken in the areas of trial
design highlighted here by our interviewees (recruit-
ment, organisation, flexibility of adherence, flexibility of
delivery, and follow-up) where a completely pragmatic
approach may not be best. The lack of universal under-
standing of the term “pragmatic trial” shows a need for
promoting better understanding of pragmatic trials and
a need for those conducting pragmatic trials to be expli-
cit about how their trial is, and is not, pragmatic. The
PRECIS-2 tool can assist with defining how pragmatic a
trial is and could be used to help people understand
what it means for a trial to be pragmatic. Good reporting
of trials is important for ensuring their applicability, par-
ticularly details of the intervention delivered and what
constitutes usual care in the clinical setting in which the
intervention is being evaluated.
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